lifespan • research brief
Yamanaka Factors at Scale: The Race to Reprogram Aging
Partial cellular reprogramming has reversed aging in mice. Now the hard work begins: making it safe for humans.
Dr. James Liu • Feb 7, 2026 • 10 min
Latest
View all →
lifespan / news
Altos Labs One Year Later: Progress and Promises
The world's best-funded longevity company has been notably quiet. Here's what we know about what they're building.
Marcus Webb • Jan 28, 2026 • 8 min
healthspan / deep dive
Rapamycin Goes Mainstream: A User's Guide
The most promising longevity drug is finding its way into wellness clinics and biohacker forums. Here's what the science actually says.
Dr. Sarah Chen • Jan 25, 2026 • 18 min
healthspan / news
The Glucose Revolution: CGMs Beyond Diabetes
Continuous glucose monitors were designed for diabetics. Now they're the must-have wearable for the metabolically curious.
Marcus Webb • Jan 20, 2026 • 7 min
business / news
Longevity Biotech Sees Record Funding in Early 2024
Investment in aging research companies surges as institutional investors bet big on healthspan extension technologies.
Editorial Team • Feb 10, 2024 • 6 min
business / analysis
10 Longevity Startups to Watch in 2024
From cellular reprogramming to AI-powered drug discovery, these companies are pushing the boundaries of aging research.
Sarah Chen • Feb 5, 2024 • 8 min